Peripheral Facial Paralysis After COVID-19 Vaccination

Öz

Acute peripheral facial paralysis (PFP) is an acute facial weakness of various etiologies. Idiopathic Bell’s palsy is the most common cause. Viruses such as herpes zoster and human immunodeficiency virus, autoimmune diseases, Lyme disease, Kawasaki disease, Guillain-Barre and Melkersson-Rosenthal syndrome, ear trauma, temporal bone fractures, barotrauma, otitis media, cholesteatoma, sarcoidosis, are other ethiological causes. Also inactivated or live attenuated vaccines like influenza vaccine can be associated with several neurological complications, such as Guillain–Barre syndrome and chronic inflammatory demyelinating polyneuropathy and PFP. The coronavirus (COVID-19) pandemic has been a threat to millions of people all over the world and the development of effective and safe vaccines against this virus has been the first aim of researchers. Coronavac which is an inactivated COVID-19 vaccine form is used to immunize patients in some of the countries.
Case Report: A 72-year-old female with hypertension developed right-sided facial muscle weakness the days after the second injection of the Coronavac vaccine. She had no history of COVID-19 infection and PCR testing was negative. She had not mentioned cold exposure. Examinations showed right PFP House Brackman stage 5 with partial eyelid closure but no other muscle activation. Her cranial computerized tomography was normal, she was advised to use oral treatment of glucocorticoid, artificial tear drops, and get rehabilitation for paralysis. Electromyographic (EMG) findings at the end of the first month indicated partial axonal damage of the right facial nerve.
Conclusions: This case is an anecdotal incident and no cause and effect can be concluded at this time. But Coronavac may be the cause of peripheral facial palsy in our patient.

Anahtar Kelimeler

• facial paralysis
• covid
• vaccination

Kaynakça

1. Referans 1-Jowett N (2018) A general approach to facial palsy. Otolaryngol Clin North Am 51:1019–1031.
2. Referans2-Mattox DE. Clinical disorders of the facial nerve. In: Flint PW, HaugheyBH, Lund VJ, Niparko JK, Richardson MA, Robbins KT, et al.,editors. Cummings Otolaryngology: Head&Neck Surgery. 6th ed. Philadelphia, PA: Elsevier Science Health Science;2014. p.2617-28
3. Referans3-Rath B,Gidudu JF, Anyoti H et al. Facial nerve palsy including Bells' palsy: case definitions and guidelines for collection, analysis and presentation of immunisation safety data. Vaccine 2017;35:1972-83
4. Referans4- Haber P, De Stefano F, Angulo FJ, Iskander J, Shadomy SV, WeintraubE, Chen RT. Guillain–Barré syndrome following influenza vaccination. JAMA. 2004;292(20):2478–81.
5. Referans5-Kelkar P. Chronic inflammatory demyelinating polyneuropathy(CIDP) with rapid progression after influenza vaccination: a report of three cases. J Clin Neuromuscul Dis. 2006;8:20–5.
6. Referans6- Alcalde-Cabero E, Almazán-Isla J, García López FJ, et al. Guillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital discharge database. BMC Neurol. 2016;16:75.
7. Referans7-Chang KH, Lyu RK, Lin WT, Huang YT, Lin HS, Chang SH. Gulllain–Barre syndrome afte rtrivalent influenza vaccination in adults. Front Neurol. 2019;10:768
8. Referans8-Nicola Cirillo Reported orofacial adverse effects of COVID-19vaccines: The knowns and the unknowns J Oral Pathol Med. 2021;00:1–4.

9. Referans9-Asaf S, Eran P, Idan H Peripheral facial nerve palsy following BNT162B2(COVID-19) vaccination IIMAJ 2021;23: 143-144
10. Referans10-House JW, Brackmann DE (1985) Facial nerve grading system Otolaryngol Head Neck Surg 93:146–147.)
11. Referans11- ZhangW,Xu L, LuoT,Wu F, Zhao B, LiX (2020) The etiology of Bell’s palsy: a review. J Neurol 267:1896–1905.
12. Referans12- Nunes Duarte-Neto A, de Almeida Monteiro RA, da Silva LFF et al (2020) Pulmonary and systemic involvement of COVID-19 assessed by ultrasound-guided minimally invasive autopsy. Histopathology. 77:186–197.
13. Referans13-Murdin A. D.,Barreto L., Plotkin S., Inactivated poliovirus vaccine: Past and present experience. Vaccine 14, 735–746 (1996).
14. Referans14-Vellozzi C.,Burwen D. R., Dobardzic A., Ball R., Walton K., Haber P., Safety of trivalent inactivated influenza vaccines in adults: Background fo rpandemic influenza vaccine safety monitoring. Vaccine 27, 2114–2120 (2009).
15. Referans15-Agmon-Levin N, Kivity S, Shoenfeld Y. Influenza vaccine and autoimmunity IMAJ 2009;11(3): 183-5
16. Referans16- Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2020; 21(2):181-192
17. Referans17-Avcı H, Karabulut B, Eken HD, Faraşoğlu A, Çakil T, Çoruk S, Özel H, Kaya NK, Özbalta SÖ. Otolaryngology-Specific Symptoms May Be Highly Observed in Patients With a History of Covid-19 Infection After Inactivated Coronavirus Vaccination. Ear Nose Throat J. 2021 Jul 8
18. Referans 18-Lu L, Xiong W, Mu J, et al. The potential neurological effect of the COVID-19 vaccines: A review. Acta Neurol Scand. 2021;144(1):3-12.
19. Referans19-Shin MD, Shukla S, Chung YH, et al. COVID‐19 vaccine development and a potential nanomaterial path forward. Nat Nanotechnol. 2020;15(8):646‐655.
20. Referans20--. Pasquale A, Preiss S, Silva F, Garçon N. Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines. 2015;3(2):320‐343.